Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience. (March 2017)

• Record Type: Journal Article
• Authors: Crespo, Guillermo; Jiménez-Fonseca, Paula; Custodio, Ana; López, Carlos; Carmona-Bayonas, Alberto; Alonso, Vicente; Navarro, Miguel; Aller, Javier; Sevilla, Isabel; Grande, Enrique; Gajate, Pablo; Alonso-Gordoa, Teresa; Matos, Ignacio; Capdevila, Jaume; Nieto, Beatriz; Barriuso, Jorge
• Is Part Of: Future oncology. Volume 13:Number 7(2017)
• Page Start: 615
• Page End: 624
• Publication Date: 2017-03
• Subjects: capecitabine -- carcinoids -- neuroendocrine tumors -- pancreatic neuroendocrine tumors -- retrospective study -- temozolomide; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2016-0434
• Languages: English
• ISSNs: 1479-6694

Abstract

Background & methods: Capecitabine and temozolomide chemotherapy was used in 65 patients with grade 1/2 neuroendocrine tumors (NETs). 46 patients (70.8%) had pancreatic NETs (pNETs).Results: Response rate was 47.7%, with two complete responses (3.1%), 29 partial responses (44.6%) and 27 patients (41.5%) achieved stable disease. Median progression-free survival was 16.1 months (95% CI: 10.7–21.6) and overall survival was 38.3 months (95% CI: 24.6–51.9). Differences in progression-free survival and overall survival between pNETs and non-pNETs were not found. Nine (13.8%) patients experienced grade 3/4 toxicities, mainly thrombocytopenia (10.8%) and neutropenia (7.7%).Conclusion: This is the largest reported series of NETs treated with capecitabine and temozolomide in daily practice and shows that this combination is a promising treatment option for both grade 1/2 pNETs and non-pNETs.